BusinessWorld reports on a newer class of weight loss drugs that it says is beating Ozempic on results.
Recap by typeshit. Full story at BusinessWorld Online.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
The review covers adults with a BMI over 30, or 27 to 30 with a weight-related condition. Prof Michael Barry says funding it may need a wider shift in health policy.
MedShadow rounds up FDA recalls at three compounders, including Carolina Infusion and Apothecary Pharma, plus inspection findings on sterile processing.
Loading…